Last reviewed · How we verify
bisphosphonates, calcium, and vitamin D
At a glance
| Generic name | bisphosphonates, calcium, and vitamin D |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Romosozumab Use to Build Skeletal Integrity (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women (PHASE4)
- Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis
- Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease (PHASE4)
- Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
- Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover (PHASE4)
- Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bisphosphonates, calcium, and vitamin D CI brief — competitive landscape report
- bisphosphonates, calcium, and vitamin D updates RSS · CI watch RSS
- Pfizer portfolio CI